SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* AMGEN INC (Last) (First) (Middle) ONE AMGEN CENTER DRIVE (Street) THOUSAND OAKS CA 91320 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol TETRALOGIC PHARMACEUTICALS CORP [ TLOG ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/17/2013
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2013		C		448,767	A	$0(2)	448,767	D
Common Stock	12/17/2013		C		268,116	A	$0(2)	268,116	I	By Ventures(1)
Common Stock	12/17/2013		X		1,141(3)	A	$6.4022(2)	269,257	I	By Ventures(1)
Common Stock	12/17/2013		P		272,142	A	$7	541,399	I	By Ventures(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Notes	$7(2)	12/17/2013		C			$3,000,000	(2)	(2)	Common Stock	448,767	$0(2)	0	D
Series B Convertible Preferred Stock	(2)	12/17/2013		C			108,932	(2)	(2)	Common Stock	108,932	$0(2)	0	I	By Ventures(1)
Series C Convertible Preferred Stock	(2)	12/17/2013		C			117,361	(2)	(2)	Common Stock	117,361	$0(2)	0	I	By Ventures(1)
Convertible Notes	$7(2)	12/17/2013		C			$279,103	(2)	(2)	Common Stock	41,823	$0(2)	0	I	By Ventures(1)
Series C Convertible Preferred Stock Warrants (Right To Buy)	$6.4022(2)	12/17/2013		X			13,355	(2)	(2)	Common Stock	13,355	$0(2)	0	I	By Ventures(1)

1. Name and Address of Reporting Person* AMGEN INC (Last) (First) (Middle) ONE AMGEN CENTER DRIVE (Street) THOUSAND OAKS CA 91320 (City) (State) (Zip)

1. Name and Address of Reporting Person* Amgen Ventures LLC (Last) (First) (Middle) ONE AMGEN CENTER DRIVE (Street) THOUSAND OAKS CA 91320 (City) (State) (Zip)

Explanation of Responses:

1. Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

2. As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock.

3. In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures.

	/s/ David J. Scott Senior Vice President, General Counsel and Secretary on behalf of Amgen Ventures LLC and Amgen Inc.	12/17/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.